Opinion|Videos|February 16, 2026
Opportunities for Health Systems to Integrate APPs Into Alzheimer Disease Care
Author(s)Ken Cohen, MD, FACP
Panelists discuss how system-wide APP integration improves coordinated, efficient Alzheimer care.
Advertisement
Episodes in this series
Panelists discuss how incorporating advanced practice providers (APPs) into structured health-system pathways expands capacity for Alzheimer diagnosis and management. Their integration supports timely evaluations and consistent follow-up.
Panelists discuss how organizational policies that empower APPs enhance operational efficiency, improve patient throughput, and alleviate physician workload. Systemwide collaboration ensures equitable care access.
Panelists discuss how embedding APPs within multidisciplinary teams also reduces long-term costs and supports sustainable models for chronic neurodegenerative disease management.
Advertisement
Related to this article
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.
Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
5